Activation of Haem-Oxidized Soluble Guanylyl Cyclase with BAY 60-2770 in Human Platelets Lead to Overstimulation of the Cyclic GMP Signaling Pathway
Open Access
- 8 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e47223
Abstract
Nitric oxide-independent soluble guanylyl cyclase (sGC) activators reactivate the haem-oxidized enzyme in vascular diseases. This study was undertaken to investigate the anti-platelet mechanisms of the haem-independent sGC activator BAY 60-2770 in human washed platelets. The hypothesis that sGC oxidation potentiates the anti-platelet activities of BAY 60-2770 has been tested. Human washed platelet aggregation and adhesion assays, as well as flow cytometry for αIIbβ3 integrin activation and Western blot for α1 and β1 sGC subunits were performed. Intracellular calcium levels were monitored in platelets loaded with a fluorogenic calcium-binding dye (FluoForte). BAY 60-2770 (0.001–10 µM) produced significant inhibition of collagen (2 µg/ml)- and thrombin (0.1 U/ml)-induced platelet aggregation that was markedly potentiated by the sGC inhibitor ODQ (10 µM). In fibrinogen-coated plates, BAY 60-2770 significantly inhibited platelet adhesion, an effect potentiated by ODQ. BAY 60-2770 increased the cGMP levels and reduced the intracellular Ca2+ levels, both of which were potentiated by ODQ. The cell-permeable cGMP analogue 8-Br-cGMP (100 µM) inhibited platelet aggregation and Ca2+ levels in an ODQ-insensitive manner. The cAMP levels remained unchanged by BAY 60-2770. Collagen- and thrombin-induced αIIbβ3 activation was markedly inhibited by BAY 60-2770 that was further inhibited by ODQ. The effects of sodium nitroprusside (3 µM) were all prevented by ODQ. Incubation with ODQ (10 µM) significantly reduced the protein levels of α1 and β1 sGC subunits, which were prevented by BAY 60-2770. The inhibitory effects of BAY 60-2770 on aggregation, adhesion, intracellular Ca2+ levels and αIIbβ3 activation are all potentiated in haem-oxidizing conditions. BAY 60-2770 prevents ODQ-induced decrease in sGC protein levels. BAY 60-2770 could be of therapeutic interest in cardiovascular diseases associated with thrombotic complications.Keywords
This publication has 57 references indexed in Scilit:
- Insight into the Rescue of Oxidized Soluble Guanylate Cyclase by the Activator CinaciguatChemBioChem, 2012
- The Soluble Guanylate Cyclase Stimulator BAY 41-2272 Inhibits Vascular Smooth Muscle Growth through the cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase PathwaysThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Heme Oxygenase-1 Deficiency Leads to Alteration of Soluble Guanylate Cyclase Redox RegulationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Structure of Cinaciguat (BAY 58–2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl CyclaseJournal of Biological Chemistry, 2010
- The anti‐aggregating effect of BAY 41‐2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxideBritish Journal of Pharmacology, 2010
- Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation‐induced degradationBritish Journal of Pharmacology, 2009
- Antigrowth Properties of BAY 41-2272 in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 2009
- Probing the presence of the ligand‐binding haem in cellular nitric oxide receptorsBritish Journal of Pharmacology, 2008
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006